

## COMPANY PROFILE

### Market:

An estimated two million individuals seek medical treatment for head trauma in the U.S. each year, and the worldwide incidence of head trauma is estimated at approximately ten million individuals. While CT scans are currently the diagnostic standard for hematomas, many head trauma patients do not immediately receive a CT scan due to logistics related to accident site and in many remote areas, due to lack of CT scan equipment availability. Yet for patients with brain hematomas, prompt remedial action is essential to maximize preservation of life and brain function. The Infrascanner addresses this unmet medical need for a simple, portable, accurate, and cost effective hematoma detection device for use in a variety of settings, including hospital emergency rooms and intensive care units. Inherent in its portable design the Infrascanner may conveniently be used as at bedside, eliminating the need for patients being transported to an imaging center. The Infrascanner also has potential for use in emergency medical vehicles, in developing world medical clinics and in battlefield and disaster zones.

### Technology Platform:

Based on the patented work of Dr. Britton Chance at the University of Pennsylvania and Dr. Claudia Robertson at Baylor College of Medicine, the Infrascanner unit is a small, portable, handheld device based on a PDA platform with a wireless detector sensor. It detects hematoma based on the differential NIR light absorption of the bleeding versus the non-bleeding part of the brain, made possible by the unique light-absorbing property of the hemoglobin in the blood. Revenues from the sale of Infrascanner consist of the sale of the base detector unit and the disposable sterile part of the sensor.

### Management Team:

**Dr. Baruch Ben Dor** - President and CEO. Dr. Ben Dor is a Physics Ph.D. and a graduate of the highly prestigious "Talpiot" academy of the Israeli Air Force with 21 years industrial hands-on experience in research and development, sales and marketing and general management.

Most recently he was involved in all aspects of product commercialization and global product sales working as general manager of a medical device start up.

**Randy Langston** – VP of Sales and Marketing. Mr. Langston has 32 years experience in Medical Devices Sales and Marketing. He was Director of Market Development at Advanced Neuromodulation Systems, VP Neurologic Technologies International at Medtronic / Sofamor Danek, and National Sales Manager of Codman & Shurtleff, a division of Johnson & Johnson.

**David L. Solt** – Vice President for Research and Development. Mr. Solt is an Electrical Engineer with 17 years of experience in medical electronic devices development and 15 years in military and commercial communications. Prior to joining InfraScan, Inc., Mr. Solt was directing the research team and leading the manufacturing team at Valley Forge Scientific Corp. and has also founded Omnitrionix in the past.

**Prof. Banu Onaral** – Chairman of the Board. Prof. Onaral is the Director of the School of Biomedical Engineering at Drexel University. Her academic research is focused on bio-medical signal processing. Prof. Onaral served as the President of the IEEE Engineering in Medicine and Biology Society.

**Prof. Britton Chance** - Chairman of Advisory Board and inventor of key technology. Prof. Chance is Professor Emeritus of Biophysics and Director of Foundation for Medical Physics at the University of Pennsylvania. He is an acknowledged thought leader in biophysics - published more than 2,000 scientific articles and numerous books.

### Clinical Data:

A multi-center study with the Infrascanner involving 431 patients demonstrated high sensitivity and specificity for detecting bleeding in the brain. Those results were used to obtain CE Mark for the product and launch sales internationally..

### Pipeline:

A second market application for Infrascanner (after hematoma) is stroke. In stroke, the crucial information needed to start treatment is the type of stroke (whether ischemic or hemorrhagic) and the Infrascanner will allow the first responder to diagnose and start the treatment of stroke much earlier than it is possible today. There are more than 700,000 strokes annually in the US. Stroke is the leading cause of long-term disability in the USA and the main reason for that is that the current diagnostics and treatment start too late.



## INVESTORS & FINANCING

InfraScan, Inc. is funded by \$1.5 million convertible loans from BioAdvance, Ben Franklin and PIDC and \$1.25 million in grants by the US Navy and Army. Currently the Company is seeking \$3 million to launch sales in the USA within a year.

## CONTACT INFORMATION

**InfraScan, Inc.**, 3508 Market Street, Philadelphia, PA 19104

Phone: (215) 387-6784, Fax: (215) 386-2327, Email: [info@infrascanner.com](mailto:info@infrascanner.com), Web: [www.infrascanner.com](http://www.infrascanner.com)